Kolling Institute, University of Sydney, Royal North Shore Hospital, Sydney, Australia.
Osteoarthritis Cartilage. 2013 Jul;21(7):939-42. doi: 10.1016/j.joca.2013.04.014. Epub 2013 Apr 30.
The sixth Osteoarthritis Research Society International (OARSI) Workshop on Imaging in Osteoarthritis combined with the third osteoarthritis (OA) Biomarkers Workshop is the first to bring together the imaging and molecular biomarker communities to focus on clinical validation and qualification of OA biomarkers. The workshop was held in Hilton Head, SC, USA, from June 12-14, 2012; 138 attendees participated, including representatives from academia, pharmaceutical and magnetic resonance imaging (MRI) industries, Food and Drug Administration (FDA), and National Institutes of Health (NIH). Presentations and discussions raised awareness, consolidated knowledge, and identified strategies to overcome challenges for the development and application of imaging and biochemical biomarkers in OA research studies and clinical trials.
The OA research communities need to work alongside regulatory agencies across the world, to qualify and validate new chemical and imaging biomarkers for future research and clinical trials.
第六届骨关节炎研究学会国际（OARSI）骨关节炎影像学研讨会与第三届骨关节炎（OA）生物标志物研讨会联合召开，首次汇聚影像学和分子生物标志物两个领域的专家，重点关注 OA 生物标志物的临床验证和确证。该研讨会于 2012 年 6 月 12 日至 14 日在美国南卡罗来纳州希尔顿头市举行；共有 138 名代表参加，包括学术界、制药和磁共振成像（MRI）行业、美国食品药品监督管理局（FDA）和美国国立卫生研究院（NIH）的代表。会议报告和讨论提高了认识，巩固了知识，并确定了策略，以克服在 OA 研究和临床试验中开发和应用影像学和生化生物标志物的挑战。
OA 研究界需要与世界各地的监管机构合作，为未来的研究和临床试验鉴定和验证新的化学和影像学生物标志物。
